Novavax Debt To Equity from 2010 to 2024

NVAX Stock  USD 8.47  0.43  5.35%   
Novavax Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity will likely drop to -0.25 in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
(0.23)
Current Value
(0.25)
Quarterly Volatility
14.60582503
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 82.31. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Novavax over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Novavax's Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 8.24 %10 Years Trend
Very volatile
   Debt To Equity   
       Timeline  

Novavax Debt To Equity Regression Statistics

Arithmetic Mean(4.36)
Geometric Mean0.16
Coefficient Of Variation(335.08)
Mean Deviation7.02
Median(0.23)
Standard Deviation14.61
Sample Variance213.33
Range57.5526
R-Value0.05
Mean Square Error229.25
R-Squared0
Significance0.87
Slope0.15
Total Sum of Squares2,987

Novavax Debt To Equity History

2024 -0.25
2023 -0.23
2022 -0.77
2021 -0.92
2020 0.51
2019 -1.72
2018 -1.9

About Novavax Financial Statements

Novavax investors use historical fundamental indicators, such as Novavax's Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity(0.23)(0.25)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.